| 3.91 -0.17 (-4.17%) | 10-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.84  |
1-year : | 5.48 |
| Resists | First : | 4.14 |
Second : | 4.69 |
| Pivot price | 4.15  |
|||
| Supports | First : | 3.25 |
Second : | 2.7 |
| MAs | MA(5) : | 4.03 |
MA(20) : | 4 |
| MA(100) : | 5.21 |
MA(250) : | 6.05 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51.9 |
D(3) : | 54.7 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 13.5 | Low : | 3.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLNN ] has closed above bottom band by 15.7%. Bollinger Bands are 47.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.11 - 4.13 | 4.13 - 4.14 |
| Low: | 3.75 - 3.77 | 3.77 - 3.8 |
| Close: | 3.86 - 3.9 | 3.9 - 3.94 |
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
Fri, 02 Oct 2026
Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision - TradingView
Tue, 22 Sep 2026
Investors can meet Clene management in New York or online through Sept. 30 - Stock Titan
Fri, 18 Sep 2026
Clene (CLNN) CEO buys more stock in board-approved deal - Stock Titan
Tue, 15 Sep 2026
A biotech's $4 million stock offering is expected to fund operations into 2027 - Stock Titan
Tue, 18 Aug 2026
Clene (NasdaqCM:CLNN) Stock Forecast & Analyst Predictions - Simply Wall Street
Mon, 17 Aug 2026
Clene to Present at the Emerging Growth Conference - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 9.76e+006 (%) |
| Held by Institutions | 16.9 (%) |
| Shares Short | 925 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.912e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 941.1 % |
| Return on Equity (ttm) | -56.9 % |
| Qtrly Rev. Growth | 197000 % |
| Gross Profit (p.s.) | 245.57 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 145263 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.92 |
| Dividend | 0 |
| Forward Dividend | 1.01e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|